Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue (2009 - 2026)

Regeneron Pharmaceuticals has reported Non-Current Deffered Revenue for 18 years, with the latest figure at $225.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue rose 6.28% year-over-year to $225.1 million; the trailing twelve-month figure through Mar 2026 stood at $225.1 million (up 6.28% YoY), and the FY2025 full-year result was $208.7 million, up 12.39% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $225.1 million, up from $208.7 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $225.1 million in Q1 2026, with the low at $33.5 million in Q1 2022.
• Average Non-Current Deffered Revenue over 5 years is $148.9 million, with a median of $185.7 million recorded in 2024.
• Year-over-year, Non-Current Deffered Revenue fell 4.77% in 2022 and soared 155.22% in 2023.
• Tracing REGN's Non-Current Deffered Revenue over 5 years: stood at $69.8 million in 2022, then surged by 81.52% to $126.7 million in 2023, then jumped by 46.57% to $185.7 million in 2024, then rose by 12.39% to $208.7 million in 2025, then gained by 7.86% to $225.1 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $225.1 million (Q1 2026), $208.7 million (Q4 2025), and $219.2 million (Q3 2025), per Business Quant data.

Peer Comparison